Renovaro Inc. Director Resigns, Officer Compensation Details
Ticker: LNAI · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1527728
| Field | Detail |
|---|---|
| Company | Renovaro Inc. (LNAI) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-departure, officer-compensation, governance
TL;DR
Renovaro director out, exec pay details filed.
AI Summary
Renovaro Inc. announced on February 28, 2024, a change in its board of directors. Specifically, Dr. Jonathan Roth, a director, resigned from his position. The company also reported on compensatory arrangements for its officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, while details on officer compensation are important for understanding executive incentives.
Risk Assessment
Risk Level: low — The filing primarily concerns director resignation and officer compensation, which are routine corporate events with no immediate indication of significant financial distress or major strategic shifts.
Key Players & Entities
- Renovaro Inc. (company) — Registrant
- Dr. Jonathan Roth (person) — Resigning Director
- February 28, 2024 (date) — Date of earliest event reported
FAQ
Who is the resigning director?
Dr. Jonathan Roth resigned from the board of directors.
What is the date of the earliest event reported in this 8-K?
The earliest event reported is dated February 28, 2024.
What are the main topics covered in this 8-K filing?
This filing covers the departure of a director, election of directors, appointment of officers, and compensatory arrangements of certain officers.
What is the company's state of incorporation?
Renovaro Inc. is incorporated in Delaware.
What is the company's SIC code?
The Standard Industrial Classification (SIC) code for Renovaro Inc. is 2834, Pharmaceutical Preparations.
Filing Stats: 472 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-03-05 17:03:35
Key Financial Figures
- $0.0001 — ch Registered Common Stock, par value $0.0001 per share RENB The Nasdaq Stock Mar
Filing Documents
- e5466_8-k.htm (8-K) — 26KB
- 0001731122-24-000345.txt ( ) — 194KB
- renb-20240228.xsd (EX-101.SCH) — 3KB
- renb-20240228_lab.xml (EX-101.LAB) — 33KB
- renb-20240228_pre.xml (EX-101.PRE) — 22KB
- e5466_8-k_htm.xml (XML) — 4KB
02 Departure of Directors or Principal
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Luisa Puche tendered her resignation as Chief Financial Officer of Renovaro Inc. (the "Company"), effective as of March 21, 2024. She submitted her resignation on February 28, 2024. An experienced Interim-CFO candidate has been identified. The Company has entered into contract negotiations in an effort to provide overlap with Ms. Puche to help ensure a smooth transition. In addition, Ms. Puche has agreed to continue, if needed, in a consulting role. Ms. Puche's resignation is not a result of any disagreement between herself and the Company, its management, the Company's Board of Directors (the "Board") or any committee of the Board. The Company appreciates Ms. Puche's diligent service as Chief Financial Officer and wishes her success in her future endeavors.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RENOVARO INC. By: /s/ Mark Dybul, M.D. Name: Mark Dybul Title: Chief Executive Officer Date: March 5, 2024